volume 80 pages 106174

Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice

Publication typeJournal Article
Publication date2020-03-01
scimago Q1
wos Q1
SJR1.239
CiteScore7.2
Impact factor4.7
ISSN15675769, 18781705
Pharmacology
Immunology
Immunology and Allergy
Abstract
MOTS-c (mitochondrial open-reading-frame of the twelve S rRNA-c), a mitochondrial-derived 16-amino acid peptide, targets the methionine-folate cycle, increases 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) levels, and eventually activates AMP-activated protein kinase (AMPK). AMPK activation can attenuate neutrophil pro-inflammatory activity and attenuates lipoteichoic acid (LTA) and lipopolysaccharide (LPS) induced acute lung injury (ALI) in mice. However, to our knowledge, the role of MOTS-c in LPS-induced ALI remains unclear. Hence, we investigated the potential effectiveness and underlying mechanism of MOTS-c against LPS-induced ALI in mice. The intraperitoneal administration of MOTS-c (5 mg/kg, i.p., bid, 6 days) before intratracheal LPS instillation attenuated body weight loss and pulmonary edema, inhibited neutrophilic tissue infiltration in lung tissue, downregulated the expression of cytokine-induced neutrophil chemoattractant-1 (CINC-1) and intercellular cell adhesion molecule-1 (ICAM-1) in lung tissues, decreased the levels of TNF-α, IL-1β, and IL-6, and increased the expression of IL-10 and SOD in serum, lung tissue, and bronchoalvelolar lavage fluid (BALF). Moreover, MOTS-c treatment significantly promoted p-AMPKα and SIRT1 expression and suppressed LPS-induced ERK, JNK, p38, p65, and STAT3 activation in the mouse lung tissues. Collectively, these findings suggest that MOTS-c plays important roles in protecting the lungs from the inflammatory effects of LPS-induced ALI. The effects of MOTS-c are probably orchestrated by activating AMPK and SIRT1, inhibiting ERK, JNK, p65, and STAT3 signaling pathways. Thus, MOTS-c appears to be a novel and promising candidate for the treatment of ALI.
Found 
Found 

Top-30

Journals

1
2
Scientific Reports
2 publications, 6.06%
European Journal of Pharmacology
2 publications, 6.06%
Antioxidants
2 publications, 6.06%
American Journal of Respiratory Cell and Molecular Biology
2 publications, 6.06%
Frontiers in Nutrition
1 publication, 3.03%
Journal of Translational Medicine
1 publication, 3.03%
Acta Biochimica et Biophysica Sinica
1 publication, 3.03%
Nature Communications
1 publication, 3.03%
Redox Biology
1 publication, 3.03%
Cell Reports
1 publication, 3.03%
FEBS Open Bio
1 publication, 3.03%
Journal of Cellular and Molecular Medicine
1 publication, 3.03%
Journal of Proteome Research
1 publication, 3.03%
Mitochondrion
1 publication, 3.03%
bioRxiv
1 publication, 3.03%
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
1 publication, 3.03%
Turkish Journal of Biochemistry
1 publication, 3.03%
Medicinal Research Reviews
1 publication, 3.03%
Fundamental and Clinical Pharmacology
1 publication, 3.03%
American Journal of Physiology - Endocrinology and Metabolism
1 publication, 3.03%
International Immunopharmacology
1 publication, 3.03%
Cell Metabolism
1 publication, 3.03%
Reproductive Toxicology
1 publication, 3.03%
International Journal of Nanomedicine
1 publication, 3.03%
Biochemical and Biophysical Research Communications
1 publication, 3.03%
Sleep and Biological Rhythms
1 publication, 3.03%
Materials Today Bio
1 publication, 3.03%
Frontiers in Veterinary Science
1 publication, 3.03%
International Journal of Molecular Medicine
1 publication, 3.03%
1
2

Publishers

2
4
6
8
10
Elsevier
10 publications, 30.3%
Springer Nature
5 publications, 15.15%
Wiley
4 publications, 12.12%
Frontiers Media S.A.
2 publications, 6.06%
MDPI
2 publications, 6.06%
Taylor & Francis
2 publications, 6.06%
American Thoracic Society
2 publications, 6.06%
Oxford University Press
1 publication, 3.03%
American Chemical Society (ACS)
1 publication, 3.03%
Cold Spring Harbor Laboratory
1 publication, 3.03%
Walter de Gruyter
1 publication, 3.03%
American Physiological Society
1 publication, 3.03%
Spandidos Publications
1 publication, 3.03%
2
4
6
8
10
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
33
Share
Cite this
GOST |
Cite this
GOST Copy
Yin X. et al. Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice // International Immunopharmacology. 2020. Vol. 80. p. 106174.
GOST all authors (up to 50) Copy
Chen Q., Jing Y. Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice // International Immunopharmacology. 2020. Vol. 80. p. 106174.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.intimp.2019.106174
UR - https://doi.org/10.1016/j.intimp.2019.106174
TI - Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice
T2 - International Immunopharmacology
AU - Chen, Quan
AU - Jing, Yuanyuan
PY - 2020
DA - 2020/03/01
PB - Elsevier
SP - 106174
VL - 80
PMID - 31931370
SN - 1567-5769
SN - 1878-1705
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Yin,
author = {Quan Chen and Yuanyuan Jing},
title = {Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice},
journal = {International Immunopharmacology},
year = {2020},
volume = {80},
publisher = {Elsevier},
month = {mar},
url = {https://doi.org/10.1016/j.intimp.2019.106174},
pages = {106174},
doi = {10.1016/j.intimp.2019.106174}
}